LNCD(SH:600739)2020-04-29 16:00Financial Performance - Net profit attributable to shareholders of the listed company was CNY 142.22 million, a decrease of 76.90% year-on-year[4]. - Operating revenue for the period was CNY 3.31 billion, down 12.21% from the same period last year[4]. - Basic earnings per share were CNY 0.0930, a decrease of 76.89% year-on-year[4]. - The weighted average return on net assets was 0.66%, down 2.31 percentage points from the previous year[4]. - The company reported an operating profit of ¥182,776,584.85 in Q1 2020, down 72.8% from ¥671,482,687.37 in Q1 2019[17]. - Net profit for Q1 2020 was ¥119,403,684.67, a decline of 81.5% from ¥644,033,656.71 in Q1 2019[18]. - The total comprehensive income for Q1 2020 was ¥117,273,399.82, a significant decrease from ¥788,714,512.23 in Q1 2019[18]. - The company has not indicated any major changes in net profit expectations for the upcoming reporting period[10]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 39.62 billion, an increase of 0.92% compared to the end of the previous year[4]. - The company's cash and cash equivalents stood at ¥1,986,029,843.36, down from ¥2,133,730,165.92 in the previous year[12]. - Total current assets increased to ¥8,655,097,842.21 from ¥8,580,413,218.65 year-on-year[12]. - Current liabilities decreased to ¥10,108,952,270.44 from ¥10,300,067,889.45, a reduction of 1.85%[13]. - Total liabilities increased to ¥16,534,807,727.94 from ¥16,295,323,496.28, showing a growth of 1.47%[14]. - Long-term borrowings decreased by 50% to ¥250,000,000.00, as a result of reclassifying current portions of long-term debt[10]. - The company’s total debt, including current and non-current liabilities, remains at ¥16,295,323,496.28[29]. - Total liabilities amounted to ¥10,300,067,889.45, with current liabilities accounting for a significant portion[28]. Shareholder Information - The total number of shareholders at the end of the reporting period was 70,729[7]. - The largest shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., held 12.46% of the shares[7]. - The total number of shareholders with unrestricted shares was reported, with the top ten shareholders holding significant stakes[9]. Cash Flow - Net cash flow from operating activities was negative CNY 77.67 million, a decline of 133.00% compared to the previous year[4]. - Cash flow from operating activities showed a net outflow of ¥77,666,604.04 in Q1 2020, contrasting with a net inflow of ¥235,373,622.87 in Q1 2019[22]. - Investment activities generated a net cash outflow of ¥16,823,058.08 in Q1 2020, compared to a much larger outflow of ¥1,000,644,967.23 in Q1 2019[22]. - Financing activities resulted in a net cash outflow of ¥24,105,355.66 in Q1 2020, while the previous year showed a net inflow of ¥574,246,559.94[23]. Research and Development - R&D expenses increased by 31.69% year-on-year to ¥36,034,602.36, primarily driven by the growth in biopharmaceutical research and development[10]. - Research and development expenses for Q1 2020 were ¥36,034,602.36, an increase of 31.6% from ¥27,363,405.28 in Q1 2019[17]. Other Financial Metrics - Non-operating income and expenses totaled CNY 30.22 million, reflecting various non-recurring gains and losses[6]. - The company reported an asset impairment loss of ¥-268,791,904.39, a significant increase compared to the previous year[10]. - Investment income fell by 57.41% to ¥288,166,078.26, mainly due to a decrease in income from joint ventures[10]. - The company reported interest income of ¥64,812,302.76 in Q1 2020, an increase from ¥52,867,732.81 in Q1 2019[19].